| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Accounts payable and accrued expenses | -121,408 | -153,961 |
| Accrued offering costs | -89,984 | - |
| Due to related party | 710,857 | 635,857 |
| Accrued expenses | - | -89,984 |
| Dividend income earned on marketable securities held in trust account | - | 4,247,746 |
| Net cash used in operating activities | -278,203 | -221,685 |
| Cash withdrawn from trust account for allowable working capital purposes | 250,000 | 250,000 |
| Net cash provided by investing activities | 250,000 | 250,000 |
| Net change in cash | -28,203 | 28,315 |
| Cash and cash equivalents at beginning of period | 1,357,044 | - |
| Cash and cash equivalents at end of period | 1,328,841 | - |
Oaktree Acquisition Corp. III Life Sciences (OACC)
Oaktree Acquisition Corp. III Life Sciences (OACC)